Croma-Pharma
Daniel De Boer has a diverse work experience in the pharmaceutical and aesthetics industry. Daniel is currently working at Croma-Pharma as the Executive Vice President of Business Development & Strategy. Prior to this, they served as the Global Director of Business Development & Strategy at Croma-Pharma.
Before joining Croma-Pharma, Daniel worked at Allergan as an Associate Director of Sales from 2021 to 2022. Prior to that, they were the Global Head of Business Development Aesthetics at Galderma from 2018 to 2020.
Daniel also held various positions at Nestlé Skin Health, including Business Unit Director Aesthetic & Corrective Business, EMEA from 2017 to 2017, and Head of Aesthetic & Corrective Business from 2014 to 2016.
Their earlier experience includes working at Allergan as a Corporate Account Manager Germany from 2005 to 2014, at Biomet 3i as a Business Sales Manager from 2002 to 2005, and at Allegiance Healthcare as a Product Manager from 1995 to 1999.
Daniel De Boer earned a Master of Business Administration degree in International Management from the University of Miami Herbert Business School. Daniel attended the school from 1988 to 1993.
This person is not in any offices
Croma-Pharma
4 followers
Croma is a global player in the minimally invasive aesthetics market and a leading European manufacturer of premium quality hyaluronic acid syringes. The company offers a comprehensive and innovative aesthetics portfolio including botulinum toxin, fillers, lifting threads and biostimulators complemented by its own skincare brand. Founded in 1976 by a pharmacist couple, Croma-Pharma GmbH is a family company headquartered in Austria where it also operates its manufacturing plant. With 550 employees, 13 subsidiaries in Europe and Brazil, two joint ventures and 60 exclusive export partners, it distributes its products in 80 markets globally, including the US, Canada, China, Australia and New Zealand. It also operates as a contract manufacturer in orthopaedics and ophthalmology. For more information please visit cromapharma.com.